Paul Radspinner
President & Chief Executive Officer Flugen
Seminars
Wednesday 3rd February 2027
Harnessing the Nasal Mucosa to Drive Protective Immune Responses: Advancing the Next Generation of Intranasal Vaccines
2:00 pm
- Explore how targeting the nasal mucosa can generate differentiated immune protection by stimulating local mucosal immunity and cellular immune responses at the site of pathogen entry as well as in serum, providing a distinct immunological profile compared to traditional systemic antibody responses achieved through injectable vaccines
- Understand the historical biases as well as scientific and development challenges associated with intranasal vaccine platforms, including achieving durable immune protection, demonstrating clinical efficacy, optimizing deposition within the nasal cavity, and building confidence in alternative immune correlates of protection
- Learn how next-generation intranasal vaccines are leveraging favorable safety profiles, needle-free administration, and mucosal and serum immune activation to improve patient acceptance, expand access, and create new opportunities for preventing infectious respiratory diseases beyond traditional vaccination approaches
